A citation-based method for searching scientific literature

E Vrdoljak, N Marschner, C Zielinski, J Gligorov, J Cortes, F Puglisi, M Aapro, L Fallowfield, A Fontana, M Inbar, Z Kahan, A Welt, C Lévy, E Brain, X Pivot, C Putzu, A González Martín, S de Ducla, V Easton, G von Minckwitz. Ann Oncol 2016
Times Cited: 21







List of co-cited articles
160 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A Perez, Tamara Shenkier, David Cella, Nancy E Davidson. N Engl J Med 2007
47

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Nicholas J Robert, Véronique Diéras, John Glaspy, Adam M Brufsky, Igor Bondarenko, Oleg N Lipatov, Edith A Perez, Denise A Yardley, Stephen Y T Chan, Xian Zhou,[...]. J Clin Oncol 2011
699
47

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
David W Miles, Arlene Chan, Luc Y Dirix, Javier Cortés, Xavier Pivot, Piotr Tomczak, Thierry Delozier, Joo Hyuk Sohn, Louise Provencher, Fabio Puglisi,[...]. J Clin Oncol 2010
659
42

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Gunter von Minckwitz, Fabio Puglisi, Javier Cortes, Eduard Vrdoljak, Norbert Marschner, Christoph Zielinski, Cristian Villanueva, Gilles Romieu, István Lang, Eva Ciruelos,[...]. Lancet Oncol 2014
92
38

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
David Miles, David Cameron, Igor Bondarenko, Lyudmila Manzyuk, Juan Carlos Alcedo, Roberto Ivan Lopez, Seock-Ah Im, Jean-Luc Canon, Yaroslav Shparyk, Denise A Yardley,[...]. Eur J Cancer 2017
83
33

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Kathy D Miller, Linnea I Chap, Frankie A Holmes, Melody A Cobleigh, P Kelly Marcom, Louis Fehrenbacher, Maura Dickler, Beth A Overmoyer, James D Reimann, Amy P Sing,[...]. J Clin Oncol 2005
33

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Luca Gianni, Gilles H Romieu, Michail Lichinitser, Sergio V Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice Andre, Arlene Chan, Oleg Lipatov,[...]. J Clin Oncol 2013
180
33

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
David Cameron, Julia Brown, Rebecca Dent, Christian Jackisch, John Mackey, Xavier Pivot, Guenther G Steger, Thomas M Suter, Masakazu Toi, Mahesh Parmar,[...]. Lancet Oncol 2013
281
23

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Qing Liu, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher,[...]. Lancet Oncol 2015
93
23

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.
José R Rossari, Otto Metzger-Filho, Marianne Paesmans, Kamal S Saini, Alessandra Gennari, Evandro de Azambuja, Martine Piccart-Gebhart. J Oncol 2012
63
19


Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, André Robidoux, James N Atkins, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher,[...]. N Engl J Med 2012
320
19

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004
19


Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Eric Van Cutsem, Sanne de Haas, Yoon-Koo Kang, Atsushi Ohtsu, Niall C Tebbutt, Jian Ming Xu, Wei Peng Yong, Bernd Langer, Paul Delmar, Stefan J Scherer,[...]. J Clin Oncol 2012
348
19

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Peter A Kaufman, Ahmad Awada, Chris Twelves, Louise Yelle, Edith A Perez, Galina Velikova, Martin S Olivo, Yi He, Corina E Dutcus, Javier Cortes. J Clin Oncol 2015
246
19

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
19

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg,[...]. Lancet Oncol 2013
731
19

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
19

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, Susanne Unverzagt. Cochrane Database Syst Rev 2012
42
14

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
14

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
G von Minckwitz, S Loibl, M Untch, H Eidtmann, M Rezai, P A Fasching, H Tesch, H Eggemann, I Schrader, K Kittel,[...]. Ann Oncol 2014
89
14

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, Christelle Levy, Gilles Romieu, Jacques Bonneterre, Jean-Marc Ferrero, Pierre Kerbrat,[...]. Lancet Oncol 2016
32
14

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Joseph Gligorov, Dinesh Doval, José Bines, Emilio Alba, Paulo Cortes, Jean-Yves Pierga, Vineet Gupta, Rômulo Costa, Stefanie Srock, Sabine de Ducla,[...]. Lancet Oncol 2014
84
14

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Christoph Zielinski, István Láng, Moshe Inbar, Zsuzsanna Kahán, Richard Greil, Semir Beslija, Salomon M Stemmer, Zanete Zvirbule, Günther G Steger, Bohuslav Melichar,[...]. Lancet Oncol 2016
39
14

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
I E Smith, J-Y Pierga, L Biganzoli, H Cortés-Funes, C Thomssen, X Pivot, A Fabi, B Xu, D Stroyakovskiy, F A Franke,[...]. Ann Oncol 2011
81
14

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
Maura N Dickler, William T Barry, Constance T Cirrincione, Matthew J Ellis, Mary Ellen Moynahan, Federico Innocenti, Arti Hurria, Hope S Rugo, Diana E Lake, Olwen Hahn,[...]. J Clin Oncol 2016
69
14

The biology of VEGF and its receptors.
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter. Nat Med 2003
14

Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Miguel Martín, Sibylle Loibl, Gunter von Minckwitz, Serafín Morales, Noelia Martinez, Angel Guerrero, Antonio Anton, Bahriye Aktas, Winfried Schoenegg, Montserrat Muñoz,[...]. J Clin Oncol 2015
84
14

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, Annelie Liljegren, Richard Greil, Nataliya L Voytko, Anatoly N Makhson, Javier Cortes, Alain Lortholary, Joachim Bischoff,[...]. J Clin Oncol 2012
184
14

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
Herbert I Hurwitz, Pamela S Douglas, John P Middleton, George W Sledge, David H Johnson, David A Reardon, Dafeng Chen, Oliver Rosen. Oncologist 2013
78
14

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
D W Miles, S L de Haas, L Y Dirix, G Romieu, A Chan, X Pivot, P Tomczak, L Provencher, J Cortés, P R Delmar,[...]. Br J Cancer 2013
111
14

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Bryan P Schneider, Molin Wang, Milan Radovich, George W Sledge, Sunil Badve, Ann Thor, David A Flockhart, Bradley Hancock, Nancy Davidson, Julie Gralow,[...]. J Clin Oncol 2008
503
14

Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Simon Peter Gampenrieder, Franz Romeder, Claudia Muß, Magdalena Pircher, Sigrun Ressler, Gabriel Rinnerthaler, Rupert Bartsch, Claudia Sattlberger, Brigitte Mlineritsch, Richard Greil. Anticancer Res 2014
31
14

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
Adrian M Jubb, Kathy D Miller, Hope S Rugo, Adrian L Harris, Dafeng Chen, James D Reimann, Melody A Cobleigh, Maike Schmidt, Virginia K Langmuir, Kenneth J Hillan,[...]. Clin Cancer Res 2011
75
14


Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, Volker Heilmann, Matthias Beckmann, Ann Stähler, Christian Jackisch, Michael Hubalek,[...]. Breast Cancer Res Treat 2013
18
16

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Joyce O'Shaughnessy, David Miles, Svetislava Vukelja, Vladimir Moiseyenko, Jean-Pierre Ayoub, Guadalupe Cervantes, Pierre Fumoleau, Stephen Jones, Wing-Yiu Lui, Louis Mauriac,[...]. J Clin Oncol 2002
819
14

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Elizabeth Allen, Arnaud Jabouille, Lee B Rivera, Inge Lodewijckx, Rindert Missiaen, Veronica Steri, Kevin Feyen, Jaime Tawney, Douglas Hanahan, Iacovos P Michael,[...]. Sci Transl Med 2017
296
14

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, N Harbeck, B Aguilar Lopez, C H Barrios, J Bergh,[...]. Ann Oncol 2018
548
14

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Javier Cortes, Joyce O'Shaughnessy, David Loesch, Joanne L Blum, Linda T Vahdat, Katarina Petrakova, Philippe Chollet, Alexey Manikas, Veronique Diéras, Thierry Delozier,[...]. Lancet 2011
661
14

Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, Hope S Rugo, Stephen Jones, Seock-Ah Im, Karen Gelmon, Nadia Harbeck, Oleg N Lipatov, Janice M Walshe, Stacy Moulder,[...]. N Engl J Med 2016
14

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Véronique Diéras, Hans Wildiers, Jacek Jassem, Luc Y Dirix, Jean-Paul Guastalla, Petri Bono, Sara A Hurvitz, Anthony Gonçalves, Gilles Romieu, Steven A Limentani,[...]. Breast 2015
36
9

A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Adam Brufsky, Karen Hoelzer, Thaddeus Beck, Robert Whorf, Mark Keaton, Padma Nadella, Elisa Krill-Jackson, Joan Kroener, Edward Middleman, Michael Frontiera,[...]. Clin Breast Cancer 2011
25
9


Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
S W Lam, S M de Groot, A H Honkoop, A Jager, A J ten Tije, M M E M Bos, S C Linn, J van den Bosch, J R Kroep, J J Braun,[...]. Eur J Cancer 2014
22
9


Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
482
9

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Helena M Earl, Louise Hiller, Janet A Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Jean Abraham, Jeremy Thomas, Elena Provenzano, Luke Hughes-Davies,[...]. Lancet Oncol 2015
81
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.